Heartwire - Episode 142: Statins benefit those at much lower CV risk; so long, Plavix; ARISTOTLE: Apixaban cuts stroke risk in all types of AF; Next-generation transcatheter aortic valve looks good; 2012 European HF guidelines

Summary: For the week ending May 25, 2012 we discuss the following top cardiology news from heartwire: • Statins benefit those at much lower CV risk • So long, Plavix, what a ride! Clopidogrel patent expires • Apixaban cuts stroke risk in all types of AF, says ARISTOTLE • Next-generation transcatheter aortic valve looks good in 30-day registry data • 2012 European HF guidelines cover new ground: TAVI, ivabradine make debuts And also, in brief: • Missing data lead FDA panel to vote against rivaroxaban for ACS • Death and stroke rates in decline in diabetics Join us for a comprehensive review of this week's most important cardiology news.